Enzastaurin (Not yet branded)
Other Medications
Description
Enzastaurin is a selective protein kinase C beta (PKC ) inhibitor that has been evaluated as a combination therapy for metastatic colorectal cancer. The drug has been tested in maintenance regimens with 5-fluorouracil/leucovorin plus bevacizumab following first-line therapy, as well as in combination with irinotecan plus cetuximab. Enzastaurin belongs to the class of serine/threonine kinase inhibitors and was developed to target specific signaling pathways involved in tumor growth and angiogenesis.
Mechanism of Action
Enzastaurin selectively inhibits protein kinase C beta (PKC ) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways, which are critical for tumor cell proliferation, survival, and angiogenesis. By blocking these pathways, the drug aims to suppress tumor growth and reduce blood vessel formation that feeds the tumor.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.